NCT00301951View on ClinicalTrials.gov

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
LeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

sargramostim

DRUG

busulfan

DRUG

fludarabine phosphate

DRUG

mycophenolate mofetil

DRUG

tacrolimus

PROCEDURE

umbilical cord blood transplantation

Trial Locations (1)

94143-0324

UCSF Comprehensive Cancer Center, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00301951 - Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | Biotech Hunter | Biotech Hunter